Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione)

Journal of Inherited Metabolic Disease

Volumn 21, Issue 5, 1998, Pages 507-517

  Holme, E ^a   Lindstedt, S ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 4 FLUOROMETHYLBENZOYL) 1,3 CYCLOHEXANEDIONE; FUMARYLACETOACETASE; KETONE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

CHILD; CONFERENCE PAPER; DISEASE COURSE; ENZYME DEFICIENCY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; TYROSINEMIA;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; CLINICAL TRIALS; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; NITROBENZOATES; TYROSINE;

EID: 0031871486     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005410820201     Document Type: Conference Paper

References (22)

1. Dionisi-Vici C, Boglino C, Marcellini M, et al (1997) Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal. J Inher Metab Dis 20(supplement 1): 15.
2. Ellis MK, Whitfield AC, Gowans LA, et al (1995) Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)cyclohexane-1,3-dione. Toxicol Appl Pharmacol 133: 12-19.
3. Endo F, Kubo S, Awata H, et al (1997) Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 272: 24426-24432.
4. Gibbs TC, Payan J, Brett AM, Lindstedt S, Holme E, Clayton PT (1993) Peripheral neuropathy as the presenting feature of tyrosinemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. J Neurol Neurosurg Psychiatry 56: 1129-1132.
5. Grompe M, Lindstedt S, al-Dhalimy M, et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genetics 10: 453-460.
6. Holme E, Lindstedt S (1995) Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr 7: 726-732.
7. Holme E, Lindstedt S, Lock EA (1995) Treatment of tyrosinemia type I with an enzyme inhibitor. Int Pediatr 10: 41-43.
8. Kerckaert I, Poll-The BT, de Koning TJ, Roels F (1997) Secondary alterations of hepatic peroxisomes in tyrosinaemia type I: morphometry and electron microscopy. J Inher Metab Dis 20(supplement 1): 13.
9. Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91: 1816-1821.
10. Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94: 1657-1661.
11. Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74: 4641-4645.
12. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia, type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813-817.
13. Lock EA, Ellis MK, Gaskin P, et al (1998) From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inher Metab Dis 21: 498-506.
14. Mitchell G, Larochelle J, Lambert M, et al (1990) Neurologic crises in hereditary tyrosinemia. N Eng J Med 322: 432-437.
15. Perez-Cerda C, Merinero B, Sanz P, et al (1995) Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inher Metab Dis 18: 119-122.
16. Pronicka E, Rowinska E, Bentkowski Z, Zawadski J, Holme E, Lindstedt S (1996) Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase (NTBC). J Inher Metab Dis 19: 234-238.
17. Rundgren M (1977) Steady state kinetics of 4-hydroxyphenylpyruvate dioxygenase from human liver (III). J Biol Chem 252: 5094-5099.
18. Segel I (1975) Enzyme Kinetics. New York: Wiley.
19. van Spronsen FJ, Berger R, Smit GPA, et al (1989) Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inher Metab Dis 12: 339-342.
20. van Spronsen FJ, Thomasse Y, Smit GP, et al (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20: 1187-1191.
21. Vilaseca MA, Ros J, Lambruschini N, et al (1997) Chronic form of tyrosinaemia type I: late-onset treatment with NTBC. J Inher Metab Dis 20(supplement 1): 10.
22. Weinberg AG, Mize CE, Vorthen HG (1976) Occurrence of hepatoma in chronic form of hereditary tyrosinemia. J Pediatr 88: 434-438.